What is the best treatment for post-viral anosmia (loss of smell) following an upper respiratory tract infection (URTI) that occurred 6 weeks ago?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For post-viral anosmia following an upper respiratory tract infection 6 weeks ago, intranasal corticosteroids are the recommended first-line treatment, with mometasone spray (option c) being the most appropriate choice. The recommended regimen is typically one or two sprays in each nostril once daily for at least 6-8 weeks. Mometasone helps reduce inflammation in the nasal passages and olfactory epithelium, which may facilitate recovery of smell function, as supported by a study on postinfectious olfactory dysfunction 1. Oral steroids, while potentially effective, carry more systemic side effects and are generally reserved for cases that don't respond to intranasal treatment, as seen in studies on the management of post-COVID-19 symptoms 1. Decongestants are not recommended as they can cause rebound congestion with prolonged use and don't address the underlying inflammatory process affecting the olfactory neurons, as discussed in the European position paper on rhinosinusitis and nasal polyps 2020 1. Fluticasone drops are not commonly used for this condition. Patients should be advised that recovery of smell may be gradual and can take several months, with some cases benefiting from olfactory training (repeatedly smelling different essential oils daily) as an adjunctive therapy to help stimulate olfactory nerve regeneration. Key points to consider in the management of post-viral anosmia include:

  • The use of intranasal corticosteroids as the first-line treatment
  • The potential benefits of olfactory training as an adjunctive therapy
  • The limited role of oral steroids and decongestants in the treatment of post-viral anosmia
  • The importance of patient education on the potential for gradual recovery of smell and the need for prolonged treatment.

From the Research

Treatment Options for Post-Viral Anosmia

  • Decongestants: There is no direct evidence to support the use of decongestants in treating post-viral anosmia 2, 3, 4, 5, 6.
  • Oral steroids: One study found that a 15-day course of oral steroids combined with nasal irrigation may improve olfactory function, but the evidence is very uncertain 3.
  • Mometasone spray: A randomized, double-blind clinical trial found that mometasone furoate nasal spray in combination with olfactory training showed a higher improvement in severe chronic anosmia by COVID-19 compared to olfactory training alone 5.
  • Fluticasone drops: There is no direct evidence to support the use of fluticasone drops in treating post-viral anosmia 2, 3, 4, 5, 6.

Olfactory Training

  • Olfactory training is considered a promising treatment option for post-viral anosmia, and may be used in combination with other treatments such as mometasone furoate nasal spray 3, 4, 5.

Diagnosis and Pathophysiology

  • Post-viral anosmia usually occurs after an upper respiratory tract infection (URTI) and can be diagnosed based on history, clinical examination, and olfactory testing 2, 4.
  • The exact location of the damage in post-URTI anosmia is not yet known, but direct damage to the olfactory receptor cells is likely, and central mechanisms cannot be completely ruled out 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Olfactory disorders following upper respiratory tract infections.

Advances in oto-rhino-laryngology, 2006

Research

Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.

The Cochrane database of systematic reviews, 2021

Research

Post Viral Olfactory Dysfunction After SARS-CoV-2 Infection: Anticipated Post-pandemic Clinical Challenge.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2022

Related Questions

What is the most effective treatment for a patient with Upper Respiratory Tract Infection (URTI) who develops anosmia after 6 weeks?
What is the management approach for a 35-year-old male with pleuritic central chest pain following an upper respiratory tract infection (URTI)?
What is the recommended treatment for a patient with a viral Upper Respiratory Tract Infection (URTI) and a temperature of 37.7°C, currently taking paracetamol (acetaminophen) and phenylephrine?
What is the best course of treatment for a 5-year-old child with an upper respiratory tract infection (URTI) and a persistent nighttime cough, but is otherwise feeling well?
What is the best initial treatment for a pediatric patient with a runny nose, upper respiratory tract infection (URTI) symptoms, and subsequent development of frontal tenderness 3 days later?
What is the treatment for hypercalcemia?
What is the dose for treating anaphylaxis (severe, life-threatening allergic reaction)?
What is the prognosis comparison between Neonatal Myasthenia Gravis (MG) and Ocular Myasthenia Gravis (MG)?
Which has the worst Myasthenia Gravis (MG) prognosis between Muscle-Specific Kinase (MUSK), Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4), and Acetylcholine Receptor (AChR)?
A 39-year-old female presents with left subscapular pain, exacerbated by bending and lifting, which improves with Flexeril (cyclobenzaprine) and left arm extension, and radiates to the chest with deep breathing, without trauma, fever, or cardiorespiratory symptoms.
What are the effects of magnesium toxicity (hypermagnesemia)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.